Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 5/20 | 0.34 |
| ▸ | CBFB | Q13951 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517385 | 0.83 | DRD2 (0.38) | ALDH1A1POLBCBFBTP53CYP3A4 | |
| SCHEMBL477289 | 0.80 | ALDH1A1 (0.50) | ALDH1A1POLBPARP1CBFBTP53 | |
| SCHEMBL31157033 | 0.80 | ALDH1A1 (0.50) | ALDH1A1POLBPARP1CBFBTP53 | |
| SCHEMBL3969749 | 0.77 | ALDH1A1 (0.49) | ALDH1A1POLBPARP1CBFBTP53 | |
| SCHEMBL909787 | 0.76 | CBFB (0.54) | ALDH1A1POLBPARP1CBFBTP53 | |
| SCHEMBL6526190 | 0.71 | PDE5A (0.45) | ALDH1A1POLBPARP1CBFBDRD2 | |
| SCHEMBL13164363 | 0.70 | PDE5A (0.46) | ALDH1A1POLBCBFBDRD2DRD4 | |
| SCHEMBL5213800 | 0.70 | ALDH1A1 (0.45) | ALDH1A1POLBTP53HPGDSMN1; SMN2 | |
| SCHEMBL2846182 | 0.70 | CACNA1H (0.34) | POLBDRD2DRD4DRD3 | |
| SCHEMBL12847244 | 0.70 | HTR1B (0.47) | ALDH1A1POLBCBFBDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411387-B1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | VETDC INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | disclosed |
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8338414-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-1557415-B1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-06-06 | — | — | EP | disclosed |
| EP-1864665-B1 | IMMUNOSUPPRESSIVE AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| US-7750001-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070244110-A1 | Treatment of prostate cancer, melanoma or hepatic cancer | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-10-18 | — | — | US | disclosed |
| US-7153853-B2 | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060009440-A1 | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-01-12 | — | — | US | disclosed |
| EP-1557415-A1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267700-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | ALDH1A1 2283/4885POLB 4437/4885PARP1 4805/4885 |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | ALDH1A1 2617/4885POLB 136/4885PARP1 227/4885 |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | ALDH1A1 2283/4885POLB 4437/4885PARP1 4805/4885 |
| US-20060009440-A1 | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | NCOR1, NR0B1, HCAR3 | ALDH1A1 2662/4885POLB 2975/4885PARP1 1332/4885 |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | ALDH1A1 318/4885POLB 372/4885PARP1 214/4885 |
| US-20070244110-A1 | Treatment of prostate cancer, melanoma or hepatic cancer | KLK3, CYP11B1, CYP11B2 | ALDH1A1 52/4885POLB 1545/4885PARP1 2045/4885 |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | ALDH1A1 318/4885POLB 372/4885PARP1 214/4885 |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | ALDH1A1 318/4885POLB 372/4885PARP1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.